This site is intended for health professionals only

Wednesday 19 June 2019
LatestNews
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
 
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Fri, 5 Apr 2019
Immediate first-line access to this combination could be a treatment option for up to 1700 advanced kidney cancer patients in England
Fri, 5 Apr 2019
The recommendations report on emerging new evidence and expert opinion made since the first EULAR Recommendations on systemic lupus erythematosus were published in 2008
Thu, 28 Mar 2019
New immunotherapy drug targets for cancer will be progressed through a multimillion-pound drug discovery alliance between Cancer Research UK, LifeArc and Ono Pharmaceutical Co Ltd
Thu, 28 Mar 2019
ARTEMIS data demonstrate that most patients exceeded what are considered to be protective levels well before a full year of treatment
Fri, 22 Mar 2019
Cardiff University launches Medicines Discovery Institute
Thu, 21 Mar 2019
Scientists at the University of Surrey and University College London have revealed an innovative in vitro method that can help to develop easy to swallow medicine for children and older people
Wed, 20 Mar 2019
Precision-Panc seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment